What does Pivotal bioVenture Partners invest in?
Pivotal bioVenture Partners invests most often at Series B and Series A (82% of the rounds on record), in sectors such as Life Sciences, Therapeutics and Healthcare.

United States · Investor
Last cheque observed Jul 2026; 11 cheques on record.
Deploying nowNew fund $1.1M, Aug 2021VC firm
1 cheques in the last 12 months
Mostly Series B and Series A: 82% of its rounds
Sole investor in 1 rounds, median $54M
we are a life sciences venture capital firm investing in transformative therapeutic-focused healthcare companies across North America and Europe.From their own website
Every round we can evidence, newest first11 appearances
1 round
1 round
1 round
1 round
4 rounds
1 round
2 rounds
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
Named by the firm itself, on a filing, its Form ADV or its company registration7 named
We also hold 18 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
From the firm's own filings with the SEC, which it must file accurately by law
From their own portfolio page (on their website)
22fillmore
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
The investors most often in the same rounds as Pivotal bioVenture Partners. A count of rooms they were both in, not a relationship either has claimed.
The latest companies Pivotal bioVenture Partners put money into.
Pivotal bioVenture Partners invests most often at Series B and Series A (82% of the rounds on record), in sectors such as Life Sciences, Therapeutics and Healthcare.
11 investments on record, 1 of them in the last 12 months, and it led 2. The most recent was in Jul 2026.
Its most recent investments on record: Crystalys Therapeutics (Series B, Jul 2026), Mosanna Therapeutics (Series A, Jun 2025) and Zenas BioPharma (Series C, May 2024).
The median round it joins is $80M.
Yes: it led 2 of its 11 investments on record (18%).
Most of the companies it backs are in the United States (70%), Switzerland (10%) and Canada (10%).
Yes: it is actively investing, with 1 investments in the last 12 months.
Most often Longitude Capital (3 rounds together), Cormorant Asset Management (2 rounds together) and Eventide (2 rounds together).
Find the investors who back rounds like yours, and keep every conversation on one fundraising board.
Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it